Degenerative mitral valve disease is common. Up to a quarter of patients with degenerative mitral valve disease may be asymptomatic despite having severe valve regurgitation. Current guideline indications for intervention in asymptomatic patient are centred on left ventricular dimensions and ejection fraction and may include consideration in atrial fibrillation, pulmonary hypertension and those with left atrial dilatation. However, despite intervention according to these recommendations, patients remain at risk of post-operative heart failure and mortality.

Increasing adoption of non-resection valve repair in Barlow's disease has been observed in recent years. At mid-term follow-up, the clinical and echocardiographic results of MV repair for Barlow's disease were very good with low risk of mitral valve reintervention. At this time point, the results of non-resection techniques were comparable to the “gold standard” resection techniques. Monitoring of the long-term performance of non-resection techniques is warranted before definitive conclusion can be drawn.

The trial will enroll patients with moderate-to-severe or severe mitral regurgitation (MR) who are unsuitable for surgery or transcatheter edge-to-edge repair (TEER). The trial is designed with two separate non-randomised cohorts, which include moderate/severe mitral annular calcification (MAC), and a primary cohort that will include patients with no or mild MAC.

The trial will enroll patients with moderate-to-severe or severe mitral regurgitation (MR) who are unsuitable for surgery or transcatheter edge-to-edge repair (TEER). The trial is designed with two separate non-randomised cohorts, which include moderate/severe mitral annular calcification (MAC), and a primary cohort that will include patients with no or mild MAC.

In the RESHAPE-HF2 trial (NCT02444338) on which Butler is an investigator, adding mitral transcatheter edge-to-edge repair (M-TEER) to medical therapy for moderate to severe functional mitral regurgitation led to a lower rate of initial or recurrent hospitalizations for heart failure or cardiovascular death and a lower rate of total hospitalizations for heart failure at 24 months.1 Patients also showed better health status at 12 months following transcatheter mitral-valve repair compared with those receiving medical therapy alone.

Elevated RDW has emerged in cardiac surgery as a potential means of preoperative risk stratification with the capacity to predict short- and long-term postoperative mortality, acute kidney injury, and postoperative atrial fibrillation. The question as to whether perioperative hemodynamic instability may be predicted by such a marker remains a topic of ongoing debate. The aim of this study was to explore the relationship between preoperative RDW and prolonged postoperative catecholamine use in minimally invasive mitral valve surgery.

Opinions about the relative value of interventions to control mitral regurgitation secondary to heart failure might be altered by two large randomized trials. The RESHAPE-HF2 trial showed that mitral transcatheter edge-to-edge repair (M-TEER) has an advantage over guideline-recommended medical therapy alone, and the MATTERHORN trial showed M-TEER to be noninferior to surgery.

There was no difference in efficacy between transcatheter edge-to-edge repair (TEER) and surgery in patients with secondary mitral regurgitation (MR), according to late-breaking research presented in a Hot Line session today at ESC Congress 2024. The findings are published in the New England Journal of Medicine.

From new clinical guidelines to late-breaking trial results, the 2024 European Society of Cardiology (ESC) Congress in London brought together thousands of clinicians, researchers, and health care professionals to discuss the latest advances in cardiovascular medicine. The American Journal of Managed Care® spoke with lead investigators, presenters, and the chair of this year’s Congress, John McMurray, MD, in London, where they shared the meeting highlights and recapped important data.

Using peptides replicating the membrane-distal portion of CD31, which is prominently exposed on the inner side of healthy vessels, can simulate the surface of a healthy endothelium. This approach effectively prevents the deposition and activation of blood platelets and leukocytes, which are abnormally prolonged by the presence of a foreign body at sites of endovascular stent implantation, and promotes the acquisition of physiological phenotype by the ECs covering the surface.

AFMR is mainly attributed to altered structural and functional mechanics of the left atrium and the mitral valve apparatus, in the presence of AF or HFpEF. Novel imaging techniques, such as left atrial strain and late-enhancement CMR, have been shown to be associated with early disease detection and prognosis. Multimodality imaging will aid in the proper establishment of diagnostic criteria in future trials, as well as in individualized decision making in clinical practice. Finally, despite the promising results, there is a large need for randomized trials to compare the safety and efficacy of surgery vs. TEER in the setting of severe disease.

With protamine routinely given at the end of transcatheter aortic valve replacement or implantation (TAVR or TAVI), patients achieved hemostasis quicker and with greater success, according to the ACE-PROTAVI trial.

CD31-coated surfaces promoted the acquisition of a physiologic endothelial cell phenotype and rapid coverage at a significantly higher extent as compared to bare metallic surfaces in vitro. Nitinol and cobalt-chromium stents coated with CD31-mimetic peptides were rapidly integrated within the arterial wall in vivo without thrombo-inflammatory signs up to 30 days after implantation.

Through this collaboration, SMT gains an innovative product line in the Congenital Heart Defect space. This collaboration not only broadens SMT's advanced product offerings within the Congenital Heart Defect space but also marks a significant stride toward revolutionizing healthcare on a global scale.HeartX's portfolio includes advanced products like the JOVE VB Stent for Sinus Venous ASD, JOVE Versatile ASD (VASO), Fenestrated VASO and JOVE PFO, with ongoing developments in PDA and VSD closures as well as advanced visualization systems for structural interventions.

The next-generation Fenestrated Treo endograft has reliable staged expansion for a controlled deployment, with a trusted 19Fr, low-profile delivery system to treat short-neck and juxtarenal/pararenal abdominal aortic aneurysms. Fenestrated Treo offers the physician numerous key features, including the ability to reposition the graft while partially deployed; circumferential suture wraps; modified distal clasping to improve torque control; the ability to cannulate from above and below, enabling faster and safer access for dealing with narrow anatomies; and, notably, an optimal delivery time of less than five weeks.

Hemodynamic stresses are presumed to play an important role in the development of calcific aortic valve disease (CAVD). The elucidation of the shear stress mechanisms involved in the pathogenesis of CAVD has been hampered by the complexity of the native unsteady and side-specific valvular flow environment.

The stress and strain exerted on the aorta and the aortic valve induce changes directly sensed by the structural cells, and also alter the ECM, both contributing to structural alterations. Associated pathologies, such as aortic aneurysms and aortic stenosis, may result from either an enhanced intrinsic propensity of the arterial wall to dilate in response to normal biomechanics (Marfan, bicuspid valve), or as a result of pathologic biomechanical load in a given arterial segment. Several disease-specific pathophysiological processes directly depend on biomechanical factors, such as macromolecule transport, gene expression alterations, cell death pathways, calcification, inflammation, and neoangiogenesis.

The acquisition enhances the company’s TMVR technologies to address large unmet structural heart patient needs and support sustainable long-term growth, the press release goes on to state. Innovalve will join the transcatheter mitral and tricuspid therapies (TMTT) product group, led by corporate vice president, Daveen Chopra.

The type and duration of antithrombotic thrombotic treatment following LAAC remains unclear, with a wide variation in regimens used in published studies. The type of patients included in these studies (with bleeding risk ranging from low to extreme) contributes to the uncertainty regarding antithrombotic therapy selection. While mechanistic studies suggest OAC as the most appropriate regimen early after the procedure, controversial clinical data exist regarding the efficacy of different antithrombotic therapies for preventing DRT and ischemic events, especially with the use of newer LAAC devices, where lower rates of DRT have been reported. As such, avoiding major bleeding events should probably guide antithrombotic regimen selection in LAAC recipients, while taking into consideration the risk factors for DRT.

Oral anticoagulation therapy (OAC) is a mainstay for mitigating stroke and other embolic events in patients with atrial fibrillation (AF). Despite the demonstrated efficacy of OAC in reducing events, many patients are unable to tolerate OAC due to bleeding risks. Left atrial appendage occlusion (LAAO) devices were developed as implantable technologies to moderate stroke risk in patients with intolerance to OAC. Despite clinical data supporting near-comparable protection against thromboembolic events with OAC, device-related thrombus formation has emerged as a critical complication following LAAO that remains a potential limitation to the safety and efficacy of LAAO. Improved biocompatibility of LAAO devices with fluoropolymers, a well-established stent-coating technology used to reduce thrombus formation and promote endothelialization, may optimize outcomes after LAAO.